Rheumatoid Arthritis Treatment Market Size

Rheumatoid Arthritis Treatment Market size was valued at USD 33.69 billion in 2023 and is likely to reach USD 72.74 billion by the end of 2036, registering around 6.1% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of rheumatoid arthritis treatment is assessed at USD 35.33 billion.

The market growth can be attributed to the growing prevalence of rheumatoid arthritis and musculoskeletal conditions, such as, Carpal Tunnel syndrome, globally. Rheumatoid arthritis is an autoimmune disease and a chronic inflammatory disorder that affects many joints, including those in the hands and feet. It can be challenging to diagnose early because the early signs and symptoms mimic various other diseases. Currently, there is no treatment for rheumatoid arthritis; however, certain drugs are prescribed to efficiently control the conditions of rheumatoid arthritis, which include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), corticosteroids, and uric acid drugs. Furthermore, the market is projected to grow owing to the favourable government reimbursement policies, and increasing healthcare expenditure. The changing lifestyles, rising pollution levels and, changes in metabolic activities due to chronic diseases, such as, diabetes are fuelling the prevalence of rheumatoid arthritis which is projected to boost the market growth. Moreover, the increasing number of collaborations and partnerships between pharmaceutical companies, combined with the growing R&D expenditure for the treatment and novel therapies of rheumatoid arthritis is expected to drive market growth. Additionally, the rising awareness about this condition and increasing healthcare infrastructure will lead to market growth in the forecast period.